FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285809093> ?p ?o ?g. }

• W4285809093 endingPage "60" @default.
• W4285809093 startingPage "56" @default.
• W4285809093 abstract "In ORIENT-11, first-line sintilimab + pemetrexed-platinum significantly improved PFS compared with placebo + pemetrexed-platinum in patients with advanced metastatic nonsquamous non-small-cell lung cancer (AMnsqNSCLC). The study met the primary endpoint of PFS as of 15November2019. Here we report final survival analysis from ORIENT-11 (NCT03607539) using a 15September2021 data cutoff.Patients with treatment-naïve locally AMnsqNSCLC without sensitizing EGFR or ALK genomic tumor aberrations were randomly assigned to sintilimab + pemetrexed-platinum (n = 266) or placebo + pemetrexed-platinum (n = 131). Patients were stratified by PD-L1 expression, platinum-chemotherapy, and gender. Treatment continued until PD, unacceptable toxicity, or a maximum of 24 months. Patients in the placebo + pemetrexed-platinum arm could be sequenced to second-line sintilimab monotherapy, contingent upon PD. Response was assessed (RECISTv.1.1) by blinded independent radiographic review committee. Primary endpoint was PFS. OS was a secondary endpoint and defined from date of randomization to date of death due to any cause. Final OS analysis was defined as approximately 2 years after last patient randomized or when approximately 65 % of patients died, whichever first.At data cutoff of final OS analysis, median study follow-up was 30.8 months. Of 397 patients, 243 OS events were observed (sintilimab + pemetrexed-platinum:151[57 %];placebo + pemetrexed-platinum:92 [70 %]). Of the patients in placebo + pemetrexed-platinum arm, 47 % crossed over to sintilimab monotherapy per protocol. Median OS was 24.2 months in sintilimab + pemetrexed-platinum arm and 16.8 months in placebo + pemetrexed-platinum arm (HR:0.65[95 % CI:0.50,0.85]). Estimated 2-year OS rates were 50 %(sintilimab + pemetrexed-platinum) and 32 %(placebo + pemetrexed-platinum). After adjusting for the crossover effect, OS treatment effect was more pronounced with HR 0.52 (95 % CI:0.38,0.69). OS benefit across all prespecified subgroups was largely consistent with that observed in the ITT population.In the ORIENT-11 final OS analysis, sintilimab + pemetrexed-platinum demonstrated improved OS compared to placebo + pemetrexed-platinum when administered as first-line therapy in AMnsqNSCLC without EGFR or ALK genomic tumor aberrations." @default.
• W4285809093 created "2022-07-19" @default.
• W4285809093 creator A5005424988 @default.
• W4285809093 creator A5013947145 @default.
• W4285809093 creator A5015213615 @default.
• W4285809093 creator A5021139793 @default.
• W4285809093 creator A5039405375 @default.
• W4285809093 creator A5044809089 @default.
• W4285809093 creator A5047320009 @default.
• W4285809093 creator A5052712912 @default.
• W4285809093 creator A5057956678 @default.
• W4285809093 creator A5066716873 @default.
• W4285809093 creator A5070369785 @default.
• W4285809093 creator A5075302079 @default.
• W4285809093 creator A5078949281 @default.
• W4285809093 creator A5082054551 @default.
• W4285809093 creator A5089852487 @default.
• W4285809093 date "2022-09-01" @default.
• W4285809093 modified "2023-10-06" @default.
• W4285809093 title "Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study" @default.
• W4285809093 cites W1988174589 @default.
• W4285809093 cites W2802389870 @default.
• W4285809093 cites W2946386783 @default.
• W4285809093 cites W2967960429 @default.
• W4285809093 cites W3009099064 @default.
• W4285809093 cites W3047859155 @default.
• W4285809093 cites W3093317346 @default.
• W4285809093 cites W3121907365 @default.
• W4285809093 cites W3152878368 @default.
• W4285809093 cites W3183409909 @default.
• W4285809093 cites W3187725522 @default.
• W4285809093 doi "https://doi.org/10.1016/j.lungcan.2022.07.013" @default.
• W4285809093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35917647" @default.
• W4285809093 hasPublicationYear "2022" @default.
• W4285809093 type Work @default.
• W4285809093 citedByCount "15" @default.
• W4285809093 countsByYear W42858090932022 @default.
• W4285809093 countsByYear W42858090932023 @default.
• W4285809093 crossrefType "journal-article" @default.
• W4285809093 hasAuthorship W4285809093A5005424988 @default.
• W4285809093 hasAuthorship W4285809093A5013947145 @default.
• W4285809093 hasAuthorship W4285809093A5015213615 @default.
• W4285809093 hasAuthorship W4285809093A5021139793 @default.
• W4285809093 hasAuthorship W4285809093A5039405375 @default.
• W4285809093 hasAuthorship W4285809093A5044809089 @default.
• W4285809093 hasAuthorship W4285809093A5047320009 @default.
• W4285809093 hasAuthorship W4285809093A5052712912 @default.
• W4285809093 hasAuthorship W4285809093A5057956678 @default.
• W4285809093 hasAuthorship W4285809093A5066716873 @default.
• W4285809093 hasAuthorship W4285809093A5070369785 @default.
• W4285809093 hasAuthorship W4285809093A5075302079 @default.
• W4285809093 hasAuthorship W4285809093A5078949281 @default.
• W4285809093 hasAuthorship W4285809093A5082054551 @default.
• W4285809093 hasAuthorship W4285809093A5089852487 @default.
• W4285809093 hasConcept C126322002 @default.
• W4285809093 hasConcept C141071460 @default.
• W4285809093 hasConcept C142724271 @default.
• W4285809093 hasConcept C143998085 @default.
• W4285809093 hasConcept C203092338 @default.
• W4285809093 hasConcept C204787440 @default.
• W4285809093 hasConcept C27081682 @default.
• W4285809093 hasConcept C2776256026 @default.
• W4285809093 hasConcept C2776694085 @default.
• W4285809093 hasConcept C2777240266 @default.
• W4285809093 hasConcept C2778239845 @default.
• W4285809093 hasConcept C535046627 @default.
• W4285809093 hasConcept C71924100 @default.
• W4285809093 hasConceptScore W4285809093C126322002 @default.
• W4285809093 hasConceptScore W4285809093C141071460 @default.
• W4285809093 hasConceptScore W4285809093C142724271 @default.
• W4285809093 hasConceptScore W4285809093C143998085 @default.
• W4285809093 hasConceptScore W4285809093C203092338 @default.
• W4285809093 hasConceptScore W4285809093C204787440 @default.
• W4285809093 hasConceptScore W4285809093C27081682 @default.
• W4285809093 hasConceptScore W4285809093C2776256026 @default.
• W4285809093 hasConceptScore W4285809093C2776694085 @default.
• W4285809093 hasConceptScore W4285809093C2777240266 @default.
• W4285809093 hasConceptScore W4285809093C2778239845 @default.
• W4285809093 hasConceptScore W4285809093C535046627 @default.
• W4285809093 hasConceptScore W4285809093C71924100 @default.
• W4285809093 hasFunder F4320307758 @default.
• W4285809093 hasFunder F4320317608 @default.
• W4285809093 hasLocation W42858090931 @default.
• W4285809093 hasLocation W42858090932 @default.
• W4285809093 hasOpenAccess W4285809093 @default.
• W4285809093 hasPrimaryLocation W42858090931 @default.
• W4285809093 hasRelatedWork W2027821191 @default.
• W4285809093 hasRelatedWork W2055244776 @default.
• W4285809093 hasRelatedWork W2167650070 @default.
• W4285809093 hasRelatedWork W2358450743 @default.
• W4285809093 hasRelatedWork W2413020017 @default.
• W4285809093 hasRelatedWork W2606568050 @default.
• W4285809093 hasRelatedWork W2768988395 @default.
• W4285809093 hasRelatedWork W3011176692 @default.
• W4285809093 hasRelatedWork W3029430426 @default.
• W4285809093 hasRelatedWork W4254666574 @default.
• W4285809093 hasVolume "171" @default.
• W4285809093 isParatext "false" @default.

• next